| Market Capitalization (Millions $) |
540 |
| Shares
Outstanding (Millions) |
66 |
| Employees |
34 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-48 |
| Cash Flow (TTM) (Millions $) |
20 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of various diseases, primarily in the field of RNA therapeutics. The company has its headquarters in San Diego, California, and was founded in 2007 by two leading biotechnology companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc.
Regulus Therapeutics is dedicated to discovering and developing first-in-class and best-in-class medicines for the treatment of diseases like renal, hepatic, and metabolic disorders, as well as immune-oncology and neurodegenerative conditions. Regulus is involved in the development of a broad portfolio of therapeutic products for diseases such as chronic hepatitis C, liver fibrosis, and autoimmune diseases.
The company's approach is focused on research and development of microRNA (miR) therapeutics, which allows the company to harness the potent regulation of miRNA biology to treat various diseases through selective modulation of the targets of specific miRNAs. This unique approach has positioned Regulus Therapeutics as a leading player in the emerging field of RNA-based therapeutics.
Regulus Therapeutics' pipeline of development encompasses five product candidates in different stages of development for different indications. RGLS4326 is their leading product candidate; it treats Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic disease characterized by the build-up of cysts in the kidneys, which eventually leads to renal failure. Their second leading product candidate is RGLS5579, used to treat Cholangiocarcinoma, also known as bile duct cancer.
Regulus Therapeutics has collaborations with leading academic and pharmaceutical companies in the RNA therapeutics field, including Roche and Sanofi, which help the company gain access to new technologies and provide vital support in carrying out their pre-clinical and clinical studies.
In summary, Regulus Therapeutics is a cutting-edge biopharmaceutical company dedicated to the development of RNA therapeutics to and innovations that address unmet medical needs through the selective modulation of miRNA targets, with a strong focus on addressing kidney diseases and immuno-oncology.
Company Address: 4224 Campus Point Court, Suite 210 San Diego 92121 CA
Company Phone Number: 202-6300 Stock Exchange / Ticker: NASDAQ RGLS
|
10.27% 